招股信息更正说明
NewAmsterdam Pharma(NAMS)04-13 04:25
$NewAmsterdam Pharma(NAMS)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-094677 Act: 33 Size: 784 KB 网页链接
简介:NewAmsterdam Pharma Company N.V.于2019年10月17日以NewAmsterdam Pharma B.V.的名义根据荷兰法律成立为一家私人有限责任公司。NewAmsterdam Pharma于2021年10月更名为NewAmsterdam Pharma Holding B.V.。他们是一家临床阶段的生物制药公司,为心血管疾病(CVD)高危患者开发口服非他汀类药物,这些患者的低密度脂蛋白胆固醇(LDL-C或LDL)残留升高,而现有疗法对这些患者不够有效或耐受良好。作为他汀类药物的辅助药物,一种有效的、具有成本效益的和方便的低密度脂蛋白降低疗法存在着巨大的未满足需求。他汀类药物是目前高胆固醇高危CVD患者的标准护理。他们的主要候选产品obicetrapib是一种下一代口服低剂量胆固醇酯转移蛋白(CETP)抑制剂,目前正在进行四项3期和2b期临床试验,作为单一疗法和依折麦布联合疗法,用于降低LDL-C和预防主要心血管不良事件(“MACE”)。
今开:19.91 | 昨收:19.8 |
最高:20.328 | 最低:19.232 |
涨停价: | 跌停价: |
总市值:1749323641 |
NewAmsterdam Pharma(NAMS)04-13 04:25
$NewAmsterdam Pharma(NAMS)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-24-094677 Act: 33 Size: 784 KB 网页链接
NewAmsterdam Pharma(NAMS)05-09 20:05
$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-056292 Act: 34 Size: 529 KB 网页链接
NewAmsterdam Pharma(NAMS)05-10 04:25
$NewAmsterdam Pharma(NAMS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-135293 Act: 34 Size: 7 MB 网页链接
NewAmsterdam Pharma(NAMS)06-08 04:25
$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 5.07, 8.01, and 9.01 Accession Number: 0001193125-24-157374 Act: 34 Size: 207 KB 网页链接
NewAmsterdam Pharma(NAMS)04-30 05:05
$NewAmsterdam Pharma(NAMS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-122691 Act: 34 Size: 848 KB 网页链接
NewAmsterdam Pharma(NAMS)03-28 04:35
$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-037241 Size: 12 KB 网页链接
NewAmsterdam Pharma(NAMS)03-27 05:45
$NewAmsterdam Pharma(NAMS)$ 144 Report of proposed sale of securities Accession Number: 0001974158-24-000017 Act: 33 Size: 5 KB 网页链接
NewAmsterdam Pharma(NAMS)05-09 04:35
$NewAmsterdam Pharma(NAMS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055767 Act: 34 Size: 6 MB 网页链接
NewAmsterdam Pharma(NAMS)03-29 04:45
$NewAmsterdam Pharma(NAMS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009330 Size: 6 KB 网页链接
NewAmsterdam Pharma(NAMS)05-10 04:25
$NewAmsterdam Pharma(NAMS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-135282 Act: 34 Size: 848 KB 网页链接
产业链观察2023-06-05 22:18
#药闻简讯# $NewAmsterdam Pharma(NAMS)$ 宣布评估Obicetrapib的2b期剂量发现试验取得积极的顶线结果。
在接受10mg obicetrapib治疗的患者中,LDL-C中位数下降45.8%,达到了统计学意义上的主要终点(p < 0.0001)查看全文
chuminhua2023-01-19 11:01
1月17日,NewAmsterdam Pharma 宣布,其口服 CETP 抑制剂候选药物 obicetrapib 达到了 ROSE2 中期试验的主要终点,联合依折麦布用于高强度他汀类药物治疗的辅助治疗时,可显著降低低密度脂蛋白胆固醇。 据该公司称,这些数据支持将这款安进废弃的固定剂量组合推进到生物等效性和 III 期试验。https...查看全文
IPO收割机2022-11-23 23:06
$NewAmsterdam Pharma(NAMS)$ 开盘八十个点。沙发查看全文
$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-24-158751 Act: 34 Size: 216 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 5.07, 8.01, and 9.01 Accession Number: 0001193125-24-157374 Act: 34 Size: 207 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-135282 Act: 34 Size: 848 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-135293 Act: 34 Size: 7 MB 网页链接
$NewAmsterdam Pharma(NAMS)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-056292 Act: 34 Size: 529 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055767 Act: 34 Size: 6 MB 网页链接
$NewAmsterdam Pharma(NAMS)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-24-052925 Size: 20 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-122691 Act: 34 Size: 848 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-24-102926 Act: 33 Size: 243 KB 网页链接
$NewAmsterdam Pharma(NAMS)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001001 Act: 33 Size: 1 KB 网页链接